You may recall in 2011 Johnson & Johnson reduced the maximum daily dose of its Extra Strength Tylenol pain reliever, lowering the risk of accidental overdose from the drugs active ingredient acetaminophen.
Today on the blog those label changes are highlighted with the hepatitis C patient in mind.
Lucinda Porter, RN, author of Free from Hepatitis C, will be at the Hepatitis C Information and Support Group in Redwood City, CA on Thurs, April 19. Ms. Porter is a nurse who has hepatitis C a recognized hepatitis C authority and patient advocate. She will be talking about hepatitis C, following with a book signing.
Sequoia Health and Wellness Center, 749 Brewster Avenue,Redwood City, 3rd Thursday of the month, 7-8:30 PM. Free, open to all. For more information, call (650) 367-5998
A D.C. pharmacy has become the first in the nation to screen for HIV and Hepatitis C with a new rapid test—providing results in the time it takes to drink a cup of coffee.
D.C. pharmacy first to offer HIV, Hepatitis C rapid testing
The Ora-Quick HIV test is the first of its kind to detect the virus through an oral swab. The Hepatitis C test was just approved by the FDA—both give results in 20 minutes. D.C.’s Bio Scrip pharmacy is the only place in the country where you’ll find a pharmacist offering both tests
Featured in this video from YNN news in Rochester NY is Shari Foster a respected HCV advocate and old friend. Ms. Foster is the President & Chief Executive Officer of Status C Unknown, Inc. The non-profit organization was founded in response to the overwhelming need for hepatitis c public education in New York. Status C Unknown is dedicated to dispelling myths regarding this disease and providing support, testing and education to all communities.
I met Shari over ten years ago online supporting friends who were living with hepatitis C. Years later I had the privilege of meeting Shari in person at a mutual friends home here in Michigan. Our friend was in end-stage liver disease and passed away soon after, it was a difficult time for all of us. Before undergoing standard HCV therapy Shari was listed for a transplant. Please take time to read the article accompanying the video written by Marcie Fraser, here.
A program to prevent chronic hepatitis B infection in newborns seems to be working, according to a new study from researchers at the Centers for Disease Control and Prevention.
They found that more babies exposed to hepatitis B through their moms have gotten vaccinated right away, and fewer have ended up with chronic infections, since the program started in 1990.
The rollout of antiretroviral therapy in resource-limited settings provides a model for efforts to increase access to hepatitis C treatment and care in similar settings, investigators argue in the online edition of Clinical Infectious Diseases.
“Expanding access to hepatitis treatment in resource-limited settings will require a dedicated effort to overcome practical and political challenges,” comment the authors. “Perhaps the most important lesson from the scaling up of ART [antiretroviral therapy] during the last decade is that this will not happen without clear political commitment, and the engagement of civil society to hold policy makers and drug manufacturers to account.”
BC PharmaCare recently announced the reimbursement of VICTRELIS™ (boceprevir) for eligible British Columbians living with chronic hepatitis C.
Boceprevir is a first-in-class oral hepatitis C virus (HCV) protease inhibitor for the treatment of chronic hepatitis C genotype 1 infection. It is to be used in combination with peginterferon alpha and ribavirin (peg/riba) in adult patients (18 years and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous therapy.1 When added to peg/riba, boceprevir can significantly increase a patient’s chance of clearing the virus from the body.2,3 The treatment was authorized for use in Canada in July 2011.